PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX

Himangshu Sonowal, Rafael Bejar, William Rice, Stephen Howell

Open source

DOI
10.1097/01.hs9.0000973920.30384.d0
Published
8
Container
HemaSphere
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/01.hs9.0000973920.30384.d0,
  title = {PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX},
  author = {Himangshu Sonowal and Rafael Bejar and William Rice and Stephen Howell},
  year = {2023},
  journal = {HemaSphere},
  doi = {10.1097/01.hs9.0000973920.30384.d0},
  url = {https://doi.org/10.1097/01.hs9.0000973920.30384.d0}
}

RIS

TY  - JOUR
TI  - PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX
AU  - Himangshu Sonowal
AU  - Rafael Bejar
AU  - William Rice
AU  - Stephen Howell
PY  - 2023
JO  - HemaSphere
DO  - 10.1097/01.hs9.0000973920.30384.d0
UR  - https://doi.org/10.1097/01.hs9.0000973920.30384.d0
ER  - 

APA

Sonowal, H., Bejar, R., Rice, W., & Howell, S. (2023). PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX. HemaSphere. https://doi.org/10.1097/01.hs9.0000973920.30384.d0

Source records